BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Plum PS, Damanakis A, Buschmann L, Ernst A, Datta RR, Schiffmann LM, Zander T, Fuchs H, Chon SH, Alakus H, Schröder W, Hölscher AH, Bruns CJ, Bludau M. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis. J Cancer Res Clin Oncol 2021. [PMID: 34223965 DOI: 10.1007/s00432-021-03720-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Damanakis A, Plum PS, Gebauer F, Schröder W, Büttner R, Zander T, Bruns CJ, Quaas A. Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma. J Cancer Res Clin Oncol 2022. [PMID: 35477823 DOI: 10.1007/s00432-022-04025-x] [Reference Citation Analysis]
2 Zhou X, Chen H, Li S, Hua J, Zhang W, Li X, Si X, Zhang G. Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study. Cancer Control 2021;28:10732748211063955. [PMID: 34913741 DOI: 10.1177/10732748211063955] [Reference Citation Analysis]
3 Puhr HC, Preusser M, Ilhan-Mutlu A. Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? Cancers (Basel) 2021;13:4632. [PMID: 34572859 DOI: 10.3390/cancers13184632] [Reference Citation Analysis]